ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 40 for:    Clotrimazole

To Assess the Drug-drug Interaction Potential Between Dapivirine Vaginal Ring-004, Containing 25 mg of Dapivirine, and Clotrimazole 10 mg/g (1%)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02847286
Recruitment Status : Completed
First Posted : July 28, 2016
Last Update Posted : August 30, 2017
Sponsor:
Information provided by (Responsible Party):
International Partnership for Microbicides, Inc.

Brief Summary:
A Study to assess the drug-drug interaction potential, between Dapivirine Vaginal Ring-004, containing 25 MG of Dapivirine.

Condition or disease Intervention/treatment Phase
HIV- Prevention Drug: Dapivirine Ring-004 Drug: Dapivirine Ring-004 for 28 days along with clotrimazole Drug: Clotrimazole Phase 1

Detailed Description:
AN OPEN-LABEL, RANDOMISED TRIAL, WITH A THREE-PERIOD CROSSOVER PART IN HEALTHY HIV-NEGATIVE WOMEN TO ASSESS THE DRUG-DRUG INTERACTION POTENTIAL BETWEEN DAPIVIRINE VAGINAL RING-004, CONTAINING 25 MG OF DAPIVIRINE, AND CLOTRIMAZOLE 10 mg/g (1%) ADMINISTERED AS A VAGINAL CREAM, WITH A FOLLOW-ON PERIOD TO ASSESS THE EFFECT OF MULTIPLE RING REMOVALS AND RE-INSERTIONS DURING THE 28-DAY PERIOD OF THE DAPIVIRINE VAGINAL RING-004 USE ON THE SYSTEMIC AND LOCAL EXPOSURE AND RESIDUAL AMOUNT OF DAPIVIRINE IN USED RINGS

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: AN OPEN-LABEL, RANDOMISED TRIAL, WITH A THREE-PERIOD CROSSOVER PART IN HEALTHY HIV-NEGATIVE WOMEN TO ASSESS THE DRUG-DRUG INTERACTION POTENTIAL BETWEEN DAPIVIRINE VAGINAL RING-004, CONTAINING 25 MG OF DAPIVIRINE, AND CLOTRIMAZOLE 10 mg/g (1%) ADMINISTERED AS A VAGINAL CREAM, WITH A FOLLOW-ON PERIOD TO ASSESS THE EFFECT OF MULTIPLE RING REMOVALS AND RE-INSERTIONS DURING THE 28-DAY PERIOD OF THE DAPIVIRINE VAGINAL RING-004 USE ON THE SYSTEMIC AND LOCAL EXPOSURE AND RESIDUAL AMOUNT OF DAPIVIRINE IN USED RINGS
Actual Study Start Date : September 1, 2015
Actual Primary Completion Date : November 28, 2016
Actual Study Completion Date : November 28, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Treatment A
Dapivirine Ring-004 for 28 days
Drug: Dapivirine Ring-004
Treatment A: Dapivirine Ring-004 for 28 days
Other Name: Treatment A

Active Comparator: Treatment B
Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
Drug: Dapivirine Ring-004 for 28 days along with clotrimazole
Treatment B: Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
Other Name: Treatment B

Active Comparator: Treatment C
Clotrimazole, 5 g per day for 7 days
Drug: Clotrimazole
Treatment C: Clotrimazole, 5 g per day for 7 days
Other Name: Treatment C




Primary Outcome Measures :
  1. Dapivirine concentrations in plasma [ Time Frame: 28-day ]
    Dapivirine concentrations in plasma, measured at specified time points during each 28-day period that the ring is inserted, and for 14 days following ring removal

  2. Clotrimazole concentrations in plasma [ Time Frame: 7 days of once daily dosing, and for 14 days after the last administration ]
    Clotrimazole concentrations in plasma, measured at specified time points during 7 days of once daily dosing, and for 14 days after the last administration.


Secondary Outcome Measures :
  1. Dapivirine concentrations in vaginal fluid [ Time Frame: 28 days ]
    Dapivirine concentrations in vaginal fluid, collected at the cervix, measured at specified time points during each 28-day period that the ring is inserted, and for three days following ring removal.

  2. Clotrimazole concentrations in vaginal fluid [ Time Frame: 7 days of once daily dosing, and following 14 days after the last administration. ]
    Clotrimazole concentrations in vaginal fluid, measured at specified time points during 7 days of once daily dosing, and following 14 days after the last administration.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Participants must meet all the following criteria to be eligible to enrol in the trial:

  1. Women 18 and ≤ 45 years of age who can give written informed consent
  2. Available for all visits and consent to follow all procedures scheduled for the trial
  3. Healthy, based on medical history, vital signs, physical examination, urinalysis (dipstick and microscopy), laboratory evaluations for genital infections (bacterial vaginosis, gonorrhoea, chlamydia and trichomonas), and laboratory evaluations for haematology and chemistry
  4. HIV-negative as determined by an HIV test at the time of screening
  5. On a stable form of contraception, defined as:

A stable oral contraceptive regimen for at least 2 months prior to enrolment, OR Transdermal contraceptive patch for at least 3 months prior to enrolment, OR Long-acting progestins for at least 6 months prior to enrolment, OR An intra-uterine device (IUD) inserted (with no vaginal or gynaecological complaints associated with its use) at least 3 months prior to enrolment, OR Have undergone surgical sterilisation at least 3 months prior to enrolment, AND willing to use oral contraceptives if necessary to delay menstruation during the vaginal sampling period 6. Upon pelvic examination at the time of enrolment, the cervix and vagina appear normal as determined by the Investigator/Physician Asymptomatic for genital infections at the time of enrolment (if a woman is diagnosed with any treatable STI, either clinically or by laboratory test at the time of screening, she must complete treatment prior to enrolment) 8. Willing to refrain from the use of topical vaginal medications, vaginal products or objects, including female condoms, tampons, cotton wool, rags, diaphragms, cervical caps (or any other vaginal barrier method), douches, lubricants, vibrators/dildos, and drying agents for 14 days prior to enrolment and for the duration of the trial 9. Documentation of no abnormality on cervical cytology, including grossly bloody smear, within 90 days prior to screening 10. Willing to refrain from participation in any other research trial for the duration of this trial 11. Willing to provide adequate locator information for trial retention purposes and be reachable per local standard procedures, e.g. by home visit or telephone, or via family or close neighbour contacts (confidentiality to be maintained) 12. Willing to agree to abstain for a total of 2 days (48 hours) prior to each trial visit from: Penile-vaginal intercourse Oral contact with her genitalia 13. Hepatitis B and C negative at the time of screening

Exclusion Criteria:

Participants who have any of the following criteria are NOT eligible to enrol in the trial:

  1. Currently pregnant or had their last pregnancy outcome within 3 months prior to screening
  2. Currently breast-feeding
  3. Currently or within 2 months of participation in any other clinical research trial involving investigational or marketed products prior to screening
  4. Untreated symptomatic urogenital infections, e.g. urinary tract or other STIs, or other gynaecological conditions such as vaginal itching, pain, or discharge within 14 days prior to enrolment
  5. History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction, incontinence, urge incontinence or an anatomical variation that will not allow placement or retention of the ring
  6. Current vulvar or vaginal symptoms/abnormalities that could influence the trial results
  7. Cervical cytology at screening that requires cryotherapy, biopsy, treatment (other than for infection), or further evaluation
  8. Symptomatic genital herpes simplex virus (HSV) infection or a history of genital herpetic infection
  9. Any Grade 2, 3 or 4 haematology, biochemistry or urinalysis laboratory abnormality at baseline (screening) according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events; Addendum 1 Female Genital Grading Table for Use in Microbicide Studies
  10. Unexplained, abnormal bleeding per vagina during or following vaginal intercourse, or gynaecologic surgery within 90 days prior to enrolment
  11. Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of sensitivity/allergy to latex or silicone
  12. Any serious acute, chronic or progressive disease (e.g. any known history of neoplasm, cancer, diabetes, epilepsy, cardiac disease, autoimmune disease, HIV, Acquired Immunodeficiency Syndrome [AIDS], or blood dyscrasias), or signs of cardiac disease, renal failure, or severe malnutrition
  13. Have undergone a hysterectomy
  14. Any condition(s) that, in the opinion of the Investigator, might interfere with adherence to trial requirements or evaluation of the trial objectives.

    Participants who have the following criterion are NOT eligible for Treatment F:

  15. Using a hormonal intrauterine device.

Responsible Party: International Partnership for Microbicides, Inc.
ClinicalTrials.gov Identifier: NCT02847286     History of Changes
Other Study ID Numbers: IPM 036
First Posted: July 28, 2016    Key Record Dates
Last Update Posted: August 30, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No